XOCOVA Drug Patent Profile
✉ Email this page to a colleague
When do Xocova patents expire, and what generic alternatives are available?
Xocova is a drug marketed by Shionogi and is included in one NDA. There are three patents protecting this drug.
This drug has sixty patent family members in twenty-eight countries.
The generic ingredient in XOCOVA is ensitrelvir. One supplier is listed for this compound. Additional details are available on the ensitrelvir profile page.
DrugPatentWatch® Generic Entry Outlook for Xocova
Xocova will be eligible for patent challenges on May 29, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 29, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for XOCOVA?
- What are the global sales for XOCOVA?
- What is Average Wholesale Price for XOCOVA?
Summary for XOCOVA
| International Patents: | 60 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 28 |
| What excipients (inactive ingredients) are in XOCOVA? | XOCOVA excipients list |
| DailyMed Link: | XOCOVA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XOCOVA
Generic Entry Date for XOCOVA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for XOCOVA
XOCOVA is protected by three US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of XOCOVA is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Shionogi | XOCOVA | ensitrelvir | TABLET;ORAL | 220442-001 | May 29, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XOCOVA
When does loss-of-exclusivity occur for XOCOVA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 10214356
Patent: Novel triazine derivative and pharmaceutical composition containing same
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 1013642
Patent: derivado de triazina e composição farmacêutica compreendendo o mesmo
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 52269
Patent: NOUVEAU DERIVE DE TRIAZINE ET COMPOSITION PHARMACEUTIQUE LE CONTENANT (NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME)
Estimated Expiration: ⤷ Start Trial
China
Patent: 2395571
Patent: Novel triazine derivative and pharmaceutical composition containing same
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 99910
Patent: DÉRIVÉS DE TRIAZINE COMME ANTAGONISTES DES RÉCEPTEURS P2X3 ET/OU P2X2/3 ET LES COMPOSITIONS PHARMACEUTIQUES LE CONTENANT (TRIAZINE DERIVATIVES AS P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 92747
Estimated Expiration: ⤷ Start Trial
Patent: 2010092966
Patent: 新規トリアジン誘導体およびそれを含有する医薬組成物
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 11008362
Patent: DERIVADO NOVEDOSO DE TRIAZINA Y COMPOSICION FARMACEUTICA QUE COMPRENDE EL MISMO. (NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME.)
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 99910
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 99910
Estimated Expiration: ⤷ Start Trial
Russian Federation
Patent: 51845
Patent: НОВОЕ ПРОИЗВОДНОЕ ТРИАЗИНА И СОДЕРЖАЩАЯ ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING IT)
Estimated Expiration: ⤷ Start Trial
Patent: 11137531
Patent: НОВОЕ ПРОИЗВОДНОЕ ТРИАЗИНА И СОДЕРЖАЩАЯ ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING IT)
Estimated Expiration: ⤷ Start Trial
Singapore
Patent: 3647
Patent: NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 1422901
Estimated Expiration: ⤷ Start Trial
Patent: 110103470
Patent: NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 74490
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 1033183
Patent: Novel triazine derivatives and pharmaceutical compositions comprising the same
Estimated Expiration: ⤷ Start Trial
Patent: 57328
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering XOCOVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2022204775 | ⤷ Start Trial | |
| Brazil | 122023002208 | ⤷ Start Trial | |
| Canada | 3195272 | ⤷ Start Trial | |
| Chile | 2023003041 | ⤷ Start Trial | |
| China | 115038696 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch